2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206

First-in-human data for IASO206 showed that a single intravenous infusion generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study reported a 90% objective response rate and 90% MRD-negativity rate, supporting a potentially differentiated, less burdensome CAR-T treatment approach. As early-stage clinical evidence, the results are highly positive but require confirmation in larger studies.